Shares of Vera Therapeutics, Inc. (VERA) are soaring 7.48% in pre-market trading on Monday, following the company's announcement of a significant regulatory milestone. The late clinical-stage biotechnology firm has submitted a Biologics License Application (BLA) to the U.S. Food and Drug Administration (FDA) for its promising kidney disease therapy, atacicept.

The BLA submission, made through an accelerated approval program, is for the treatment of adults with immunoglobulin A nephropathy (IgAN), a serious and progressive autoimmune disease of the kidney. This move is based on positive results from a prespecified interim analysis of Vera's phase 3 trial, which met its primary endpoint of reducing proteinuria at week 36. Importantly, the safety profile of atacicept was reported to be favorable and comparable to placebo.

Investors are reacting positively to this development, as FDA approval could potentially lead to commercialization of atacicept, opening up a new market for Vera Therapeutics. The ongoing phase 3 trial, which is expected to complete in 2027, will continue to assess kidney function over two years using eGFR in a blinded, placebo-controlled design. This submission marks a critical step forward in Vera's mission to deliver transformative treatments for patients with serious immunological diseases, and the market's response reflects optimism about the company's future prospects in the competitive biotechnology sector.